Clinical Trial Update: Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating pirfenidone as a radiosensitizer in patients with head and neck squamous cell carcinoma undergoing radiotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Head and Neck Squamous Cell Carcinoma, Radiotherapy | Phase 2 | Status: UNKNOWN